warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
Janssen 54767414MMY2004: Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Botezomib and Dexamethasone (D-RVd) vs Lenalidomide, Bortezomib, and Dexamtheasone (RVd) in Subjects with Newly Diagnosed Multiple Myeloma Eligible for Hi
Brief Description  
Primary: Determine if addition of daratumumab to lenalidomide, bortezomib and dexamethasone (D-RVd) will increase the proportion of subjects achieving sCR as defined by IMWG by time of completion of post-ASCT consolidation treatment, compared with RVd alone.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Multiple Myeloma
Status  
OPEN
Start Date  
05/09/2017
IRB Number  
00019299
Principal Investigator  
Voorhees, Peter
Contact Name  
Mallory Tucker

For More Information, Contact  Mallory  , Tucker
Phone:  980-442-2011 Fax:    
Email:  Mallory.Rodgers@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close